Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication
Authors:
Open Access
- 11 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 34 (1) , 1-10
Abstract
Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for the treatment of RA in Japan in 1999 at a recommended dose of 6–8 mg/week. The approved maximum dose of MTX has been 16 mg/week since February 2011 when MTX was approved as a first-line drug in the treatment of RA. Recent evidence of MTX-polyglutamate concentration in the red blood cells of Japanese patients with RA justifies the current daily use of MTX in Japan. Additionally, after a nationwide clinical trial, a subcutaneous MTX injection formula (7.5–15 mg/week) was approved for RA treatment in September 2022. Therefore, in March 2023, a subcommittee of the Japan College of Rheumatology updated the guidance (formerly ‘guidelines’) for the use of MTX in Japanese patients with RA. This article, an abridged English translation summarizing the 2023 update of the Japan College of Rheumatology guidance for the use of MTX and management of patients with RA, will be helpful to both Japanese and global rheumatology communities.Keywords
This publication has 65 references indexed in Scilit:
- Teratogen update: MethotrexateBirth Defects Research Part A: Clinical and Molecular Teratology, 2012
- New loci associated with kidney function and chronic kidney diseaseNature Genetics, 2010
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 2009
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Annals of the Rheumatic Diseases, 2007
- Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 yearsRheumatology, 2005
- Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgeryAnnals of the Rheumatic Diseases, 2001
- Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis.Ensho, 1996
- Methotrexate bioavailability after oral and intramuscular administration in childrenThe Journal of Pediatrics, 1987